NEI Research News

A competition for radical ideas in the fight against blindness will move to its next phase by challenging participants to build functioning human retina prototypes.

The recent approval of two novel medications for glaucoma – the first new medications for the disorder in nearly 18 years – are fruit borne from decades of foundational scientific research supported by the National Eye Institute (NEI).

Common, unavoidable eye movements may be a cause of glaucoma in people with normal intraocular pressure (normal-tension glaucoma), according to new research supported by the National Eye Institute.

Scientists at the National Eye Institute (NEI) report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE) are essential for the survival of the retina’s light-sensing photoreceptors.

In a major step forward in the battle against macular degeneration, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight.

Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of the cornea.

The development of new therapies and cures would be impossible without patients volunteering for clinical research studies.

The eye is more than a window to the soul; it is a window to the brain.

A protein shaped like a 'Y' made NEI-funded scientists at Georgia Tech do a double-take may change the way they think about the protein which is sometimes implicated in glaucoma.

NIH scientists have simplified manufacturing and dosing of a potential drug candidate for the autoimmune eye disease uveitis—a vision-threatening condition that accounts for about 15 percent of blindness in the U.S.